Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by icecubeon Aug 26, 2015 1:13pm

19 Views

Post# 24052975

RE:HIGHLIGHTS THOMSON REUTERS I/B/E/S MEAN

icecube wrote:

-The score for Cipher Pharmaceuticals Inc dropped to its 3-year low of 2 this week.

-The recent change in the Average Score was due to a decline in the Earnings, Fundamental, and Relative Valuation component scores.

I should have include the report date: August 25, 2015.

Bullboard Posts

Canadian psychedelic stock to supply MDMA to Yale